glp 1 tirzepatide Decoding GLP-1 Weight Loss Medications Systemic effects of tirzepatide dually

Niu G, Wang G, Lau J, Lang L, Jacobson O, Ma Y, Kiesewetter DO, Zhang S, Chen X

But Moore said very few of her patients are using the pills

Body composition analyses have shown that both fat mass and lean mass decrease with weight loss, though fat mass accounts for the majority of weight lost

Gastrointestinal Very common (10% or more): Gastrointestinal adverse reactions (up to 73%), nausea (up to 44%), vomiting (up to 36%), diarrhea (up to 30%), constipation (up to 24.2%), abdominal pain (up to 20%) Common (1% to 10%): Dyspepsia, abdominal distension, eructation, flatulence, gastroenteritis, gastroesophageal reflux disease, gastritis, viral gastroenteritis, increased amylase, increased lipase, dry mouth, severe gastrointestinal adverse reactions, delayed gastric emptying Uncommon (0.1% to 1%): Acute pancreatitis, appendicitis Frequency not reported : Hemorrhoids, hiccups Postmarketing reports : Ileus, intestinal obstruction, severe constipation, hiccups, acute pancreatitis, necrotizing pancreatitis In clinical trials in adults using the subcutaneous injection for weight reduction, 73% of treated patients reported gastrointestinal adverse reactions, including severe reactions (4.1%)

This mode lowers their resting metabolic rate, making it more difficult to maintain weight loss following semaglutide injections